Technical Analysis for ELEV - Elevation Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.28% | |
| Wide Bands | Range Expansion | 0.28% | |
| Wide Bands | Range Expansion | 3.16% | |
| Calm After Storm | Range Contraction | -4.01% | |
| NR7 | Range Contraction | -4.01% | |
| Narrow Range Bar | Range Contraction | -4.01% | |
| Wide Bands | Range Expansion | -4.01% | |
| Calm After Storm | Range Contraction | -2.97% | |
| Earnings Movers | Other | -2.97% | |
| Inside Day | Range Contraction | -2.97% |
| Alert | Time |
|---|---|
| Possible NR7 | about 1 hour ago |
| 10 DMA Resistance | about 4 hours ago |
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Up 3% | about 4 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.89 |
| 52 Week Low | 0.363 |
| Average Volume | 1,058,119 |
| 200-Day Moving Average | 1.95 |
| 50-Day Moving Average | 4.36 |
| 20-Day Moving Average | 3.98 |
| 10-Day Moving Average | 3.70 |
| Average True Range | 0.45 |
| RSI (14) | 41.52 |
| ADX | 18.35 |
| +DI | 15.72 |
| -DI | 20.65 |
| Chandelier Exit (Long, 3 ATRs) | 3.63 |
| Chandelier Exit (Short, 3 ATRs) | 4.53 |
| Upper Bollinger Bands | 4.77 |
| Lower Bollinger Band | 3.20 |
| Percent B (%b) | 0.24 |
| BandWidth | 39.27 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.17 |
| MACD Histogram | -0.0431 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.99 | ||||
| Resistance 3 (R3) | 3.97 | 3.81 | 3.92 | ||
| Resistance 2 (R2) | 3.81 | 3.70 | 3.82 | 3.90 | |
| Resistance 1 (R1) | 3.70 | 3.64 | 3.75 | 3.72 | 3.88 |
| Pivot Point | 3.54 | 3.54 | 3.56 | 3.55 | 3.54 |
| Support 1 (S1) | 3.42 | 3.43 | 3.48 | 3.44 | 3.28 |
| Support 2 (S2) | 3.26 | 3.37 | 3.27 | 3.26 | |
| Support 3 (S3) | 3.15 | 3.26 | 3.24 | ||
| Support 4 (S4) | 3.17 |
